BridgeMD
Once-weekly petrelintide versus placebo for obesity or overweight with comorbidities
EU CTIS ID: 2024-512549-18-00
What this study is testing
To compare the dose-response of increasing doses of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity after 28 weeks of exposure
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Obtained signed informed consent prior to any trial-related procedures.
- Age above or equal to 18 years of age or above at the time of signing informed consent.
- Body mass index (BMI) ≥30.0 kg/m2 or BMI ≥27.0 kg/m2 with the presence of at least one of the following comorbidities: hypertension or dyslipidemia (treated or untreated, to be assessed at the Investigator’s discretion).
- Male or female A female participant is eligible to participate if she is: A woman of nonchildbearing potential (see definitions in Appendix 4). OR A woman of childbearing potential (WOCBP) who is not pregnant, does not intend to be pregnant, not lactating and is willing to use highly effective contraceptive methods (as required by local regulation or practice, see Appendix 4) throughout the trial and for 10 weeks after the last injection of the IMP.
- Ability to comply with the protocol requirements including self-administration of IMP with vial and syringe.
You likely can't join if
- Glycated hemoglobin (HbA1c) ≥48 mmol/mol (6.5%), as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus.
- Treatment with glucose-lowering agent(s) within 90 days prior to screening.
- A self-reported change in body weight >5% within 90 days prior to screening, irrespective of medical records.
- Treatment with any medication (prescribed or over the counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 6 months prior to screening.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.